RIGL analyst estimates
Rigel Pharmaceuticals (RIGL) analyst ratings, the average price target and its range, and every firm's latest call.
RIGL analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 17, 2026 | Piper Sandler | Rigel Pharmaceuticals price target raised to $49 from $40 at Piper Sandler | $49.00 |
| Aug 14, 2026 | H.C. Wainwright | Rigel Pharmaceuticals price target raised to $85 from $57 at H.C. Wainwright | $85.00 |
| Nov 5, 2025 | Cantor Fitzgerald | Rigel Pharmaceuticals price target raised to $38 from $32 at Cantor Fitzgerald | $38.00 |
| Nov 5, 2025 | Jefferies | Rigel Pharmaceuticals upgraded to Buy from Hold at Jefferies | $42.00 |
| Aug 17, 2022 | Piper Sandler | Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $2 | $2.00 |
| Jun 8, 2022 | Jefferies | Rigel Pharmaceuticals downgraded to Hold from Buy at Jefferies | $1.00 |
- 3 firms rate RIGL: 2 buy, 1 hold, 0 sell.
- The average price target is $67.00 from 2 analysts, from $49.00 to $85.00.
Updated 2026-11-05 12:48 UTC